References
- Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–634.
- Kuderer NM, Khorana AA, Lyman GH, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110:1149–1161.
- Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–464.
- Antic D, Milic N, Todorovic M, et al. OC-07 – Decoding risk for thromboembolic events in lymphoma patients. Thromb Res. 2016;140:S171.
- Komrokji RS, Uppal NP, Khorana AA, et al. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47:1029–1033.
- Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res. 2010;126:477–480.
- Lim SH, Woo SY, Kim S, et al. Cross-sectional study of patients with diffuse large B-cell lymphoma: assessing the effect of host status, tumor burden, and inflammatory activity on venous thromboembolism. Cancer Res Treat. 2016;48:312–321.
- Lund JL, Ostgard LS, Prandoni P, et al. Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. Thromb Res. 2015;136:917–923.
- Santi RM, Ceccarelli M, Catania G, et al. PO-03 – Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Res. 2016;140:S177.
- Wun T, White RH. Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. Thromb Res. 2010;125:S96–S102.
- Caruso V, Di Castelnuovo A, Meschengieser S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood. 2010;115:5322–5328.
- Borg IH, Bendtsen MD, Bogsted M, et al. Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2016. [Epub ahead of print]. DOI: 10.1080/10428194.2016.1185782.
- Mahajan A, Wun T, Chew H, et al. Lymphoma and venous thromboembolism: influence on mortality. Thromb Res. 2014;133:S23–S28.
- Park LC, Woo SY, Kim S, et al. Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population. Thromb Res. 2012;130:e6–e12.
- Sanfilippo KM, Wang TF, Gage BF, et al. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thromb Res. 2016;143:86–90.
- Kucher N, Puck M, Blaser J, et al. Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. J Thromb Haemost. 2009;7:1291–1296.
- Frere C, Doucet L, Farge D. Prophylaxis of venous thromboembolism in cancer patients. Expert Rev Hematol. 2016;9:535–539.
- Khorana AA, McCrae KR. Risk stratification strategies for cancer-associated thrombosis: an update. Thromb Res. 2014;133:S35–S38.
- Alexander M, Wolfe R, Ball D, et al. OC-05 – D-Dimer, fibrinogen and TEG-MA predict thromboembolism in non-small cell lung cancer – interim results from a prospective cohort study. Thromb Res. 2016;140:S170.